Table 4.

Results of additional analysis in users of tofacitinib and bDMARD.

Description of AnalysisTofacitinibbDMARDHR (Tofacitinib to the bDMARD)
NMedian PersistenceNMedian PersistenceCrudeAdjusted
New users
Medication-free gap of 90 days10310.81 (0.73–0.91)17,8031.02 (0.99–1.05)1.18 (1.09–1.28)1.14 (1.05–1.25)
At least 2 prescriptions and a medication-free gap of 90 days8051.23 (1.00–1.43)14,8261.29 (1.24–1.34)1.02 (0.93–1.13)0.99 (0.89–1.10)
Medication-free gap of 60 days10280.82 (0.73–0.91)17,7031.02 (0.99–1.05)1.18 (1.09–1.28)1.14 (1.04–1.24)
Medication-free gap of 180 days10270.81 (0.72–0.90)18,1471.02 (0.99–1.05)1.18 (1.08–1.28)1.13 (1.04–1.24)
No concomitant MTX5410.72 (0.60–0.83)68990.92 (0.87–0.96)1.15 (1.03–1.29)1.14 (1.004–1.28)
Switchers
Medication-free gap of 90 days15351.04 (0.94–1.19)98490.83 (0.78–0.86)0.90 (0.83–0.97)0.90 (0.83–0.97)
At least 2 prescriptions and a medication-free gap of 90 days12641.42 (1.26–1.63)83910.98 (0.93–1.02)0.79 (0.73–0.86)0.81 (0.74–0.88)
Medication-free gap of 60 days15381.04 (0.93–1.18)98030.83 (0.78–0.86)0.90 (0.84–0.97)0.90 (0.83–0.97)
Medication-free gap of 180 days15371.04 (0.09–1.18)97560.83 (0.78–0.86)0.90 (0.86–0.97)0.90 (0.83–0.97)
No concomitant MTX8470.90 (0.75–1.04)46840.77 (0.73–0.83)0.96 (0.87–1.06)0.94 (0.84–1.05)
  • HR for discontinuation (95% CI), where the bDMARD is the reference. Values < 1 favor tofacitinib (i.e., longer persistence with tofacitinib).

  • Median persistence (95% CI) estimated in years using Kaplan-Meier methodology.

  • No MTX treatment was defined as no dispensation or medical code for MTX in the 6 months before, and including, cohort entry. It is used as a proxy for patients who are intolerant of this medication. bDMARD: biological disease-modifying antirheumatic drug; MTX: methotrexate.